2024
Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?
Sutton T, Billingsley K, Johnson A, Corless C, Blanke C, Heinrich M, Mayo S. Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable? Journal Of Surgical Oncology 2024, 130: 40-46. PMID: 38924626, DOI: 10.1002/jso.27654.Peer-Reviewed Original ResearchHigh-risk gastrointestinal stromal tumorsRecurrence-free survivalGastrointestinal stromal tumorsResected gastrointestinal stromal tumorsAdjuvant imatinibOverall survivalStromal tumorsAdjuvant therapyDuration of adjuvant imatinibBenefit of adjuvant therapyMonths of postsurgical follow-upMultivariate Cox proportional hazards modelPostsurgical follow-upKaplan-Meier analysisCox proportional hazards modelsProportional hazards modelRadiographic recurrenceImatinib resistanceReviewed patientsFollow-upImatinibOncological treatmentCytocidal effectCancer CenterPatientsAssociation between activating GNAS mutations and outcomes with chemotherapy in metastatic appendiceal adenocarcinoma.
Gujarathi R, Rodman C, Bansal V, Belmont E, Setia N, Alpert L, Hart J, Moller M, Eng O, Lee G, Chin J, Amin M, Polite B, Liao C, Turaga K, Shergill A. Association between activating GNAS mutations and outcomes with chemotherapy in metastatic appendiceal adenocarcinoma. Journal Of Clinical Oncology 2024, 42: 4179-4179. DOI: 10.1200/jco.2024.42.16_suppl.4179.Peer-Reviewed Original ResearchAppendiceal adenocarcinomaGNAS mutationsOverall survivalActivating GNAS mutationsGNAS statusSynchronous metastasesPredictive biomarkersMetastatic disease treated with chemotherapyCox proportional hazards regression analysisGNAS activating mutationsMetastatic appendiceal adenocarcinomaProportional hazards regression analysisEvent free survivalEvent-free survivalMedian Follow-UpHazards regression analysisFree survivalRadiographic recurrenceFavorable diseaseAA patientsSurvival benefitAssociated with differential outcomesClinicopathological characteristicsClinicopathological featuresNo significant difference
2019
Positron emission tomography with 18F-fluciclovine to predict recurrence in post-treatment recurrent prostate cancer and its role in altering treatment plans.
Chong J, Muhleman M, Say R, Kostakoglu L, Ahmed J, Tewari A, Stock R, Oh W. Positron emission tomography with 18F-fluciclovine to predict recurrence in post-treatment recurrent prostate cancer and its role in altering treatment plans. Journal Of Clinical Oncology 2019, 37: 214-214. DOI: 10.1200/jco.2019.37.7_suppl.214.Peer-Reviewed Original ResearchStereotactic body radiation therapyPSA cut-offRecurrent prostate cancerRadiographic recurrenceTreatment planningPositive scansSalvage therapyProstate cancerAlteration of treatment planAltering treatment plansSalvage surgical therapyCut-offPositron emission tomographyProstate bedRadiation therapyRecurrence siteSurgical therapyLymph nodesTreatment alterationsRadiographic diseasePET/CTRecurrenceTreatment changesRisk factorsTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply